Filing Flows › International Stem Cell (ISCO) › Q2 2025
International Stem Cell (ISCO) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
International Stem Cell (ISCO) reported revenue of $2.4M for the second quarter 2025 (Q2 2025), +5% from a year earlier and +15% from the quarter before. Operating margin was 6.8%, net earnings $129K (5.3% of revenue).
International Stem Cell, Q2 2025: revenue $2.4M (+5% year over year), operating margin 6.8%, net earnings $129K, operating cash flow −$300K. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.4M | +15% | +5% |
| Operating profit | $167K | — | +12% |
| Net earnings | $129K | — | +8% |
| Operating cash flow | −$300K | -232% | — |
What changed
Revenue was $2.4M in Q2 2025, up 5% year over year and up 15% from the previous quarter. Biomedical Market was the largest line at 94% of revenue. Biomedical Market added $183K year over year (up 9%), 158% of the total change. Anti Aging Skincare Market declined 32%.
Operating profit was $167K, a 6.8% margin (up 0.4 points year over year). Of the extra revenue versus a year earlier, 16% reached operating profit, above the 6% margin then. Total costs grew 4% against revenue growth of 5%. The fastest-growing cost line was Research & development (+95%). Net earnings were $129K, up 8% year over year. The effective tax rate was 0.0%.
Operating cash flow was −$300K. Non-cash charges added back $54K of depreciation and amortization and $61K of share-based compensation. Working capital and other items used $544K. Capital expenditures of $32K exceeded it, leaving free cash flow of −$332K.
Questions
What was International Stem Cell's revenue in the second quarter 2025?
International Stem Cell (ISCO) reported revenue of $2.4M for the second quarter 2025 (Q2 2025), +5% from a year earlier and +15% from the quarter before.
Was International Stem Cell profitable in the second quarter 2025?
Operating profit was $167K (6.8% of revenue) and net earnings $129K.